Involvement of RB gene family in tumor angiogenesis. Oncogene

Experimental Chemotherapy Laboratory, Regina Elena Cancer Institute, Rome, Italy.
Oncogene (Impact Factor: 8.56). 09/2006; 25(38):5326-32. DOI: 10.1038/sj.onc.1209631
Source: PubMed

ABSTRACT Angiogenesis, the development of new blood vessels from pre-existing vessels, represents a fundamental step in tumor progression and metastatization. The induction of vasculature is required for growth of the tumor mass, to ensure an adequate supply of oxygen and metabolites to the tumor beyond a critical size. Tumor angiogenesis is a highly regulated process that is controlled physiologically by the tumor microenvironment and genetically by alteration of several oncogenes or tumor suppressor genes. We will focus on recent demonstrations regarding the involvement of the retinoblastoma family proteins (phosphorylated retinoblastoma (pRb), p107 and pRb2/p130) at different levels of the angiogenic process. pRb and its homologs can regulate the expression of pro- and antiangiogenic factors, such as the vascular endothelial growth factor, through an E2F-dependent mechanism. Moreover, pRb is able to modulate also the transcriptional activity of several angiogenesis-related factors like HIF-1, Id2 and Oct-1. pRb2/p130 is required for both differentiation and mobilization of bone marrow-derived endothelial cell precursors and endothelial sprouting from neighboring vessels. The involvement of the pRb pathway in the angiogenesis process has also been demonstrated by different cellular models expressing viral oncoproteins, like human papilloma virus. Moreover, some natural and synthetic compounds demonstrate their antiangiogenetic activity with a mechanism of action involving pRb. Finally, the possible prognostic value of immunohistochemical evaluation of pRb and/or pRb2/p130 expression can represent a useful tool for the characterization of the angiogenic phenotype of specific tumor histotypes.

Download full-text


Available from: Chiara Gabellini, Aug 18, 2015
  • Source
    • "For example, the tumor suppressor p53 positively regulates the expression of angiogenic inhibitors and negatively regulates the expression of angiogenic inducers (Volpert et al., 1997). Similarly, pRb family members regulate expression of angiogenic factors to maintain a quiescent environment (Gabellini et al., 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumor suppressors negatively regulate angiogenesis, an essential step in tumor progression. Together, HPV 16 E6 and E7 proteins, which target p53 and pRb family members, respectively, for degradation, increase the expression of two angiogenic inducers, VEGF and IL-8, in primary foreskin keratinocytes (HFKs). Conditioned media from such cells are sufficient to alter endothelial cell behavior. Here, the individual contribution of E6 and E7 to angiogenesis was investigated. E7 and, to a lesser extent E6, increased expression of VEGF and IL-8. Nevertheless, neither conditioned media from HPV 16 E6 nor E7-expressing HFKs were sufficient to induce migration of endothelial cells. Conditioned media from HFKs expressing the HPV 16 E6 and the E7 mutant E7C24G, which can target p107 and p130 but not pRb for degradation, contained increased levels of VEGF and IL-8. The results suggest that the mechanism of HPV 16 E7-mediated increased levels of VEGF is pRb-independent.
    Virology 02/2011; 410(2):283-90. DOI:10.1016/j.virol.2010.11.010 · 3.28 Impact Factor
  • Source
    • " processes that are particularly relevant to the progression of preexisting tumors . For example , autophagy is induced in hypoxic tumors . The pRb / E2F switch regulates a number of genes important for hypoxia induced autophagy ( Polager et al . , 2008 ; Tracy et al . , 2007 ) . The pRb / E2F switch also regulates genes involved in angiogenesis ( Gabellini et al . , 2006 ) . Loss of pRb could thus alleviate hypoxic stress as tumors grow and also influence the responses to that stress . We have noted above that pRb functions to enforce cellular senescence and the fidelity of mitosis . Increased chromosome instability and loss of senescence responses in the absence of pRb will also facilitate tumor progre"
    [Show abstract] [Hide abstract]
    ABSTRACT: The RB1 gene is the first tumor suppressor gene identified whose mutational inactivation is the cause of a human cancer, the pediatric cancer retinoblastoma. The 25 years of research since its discovery has not only illuminated a general role for RB1 in human cancer, but also its critical importance in normal development. Understanding the molecular function of the RB1 encoded protein, pRb, is a long-standing goal that promises to inform our understanding of cancer, its relationship to normal development, and possible therapeutic strategies to combat this disease. Achieving this goal has been difficult, complicated by the complexity of pRb and related proteins. The goal of this review is to explore the hypothesis that, at its core, the molecular function of pRb is to dynamically regulate the location-specific assembly or disassembly of protein complexes on the DNA in response to the output of various signaling pathways. These protein complexes participate in a variety of molecular processes relevant to DNA including gene transcription, DNA replication, DNA repair, and mitosis. Through regulation of these processes, RB1 plays a uniquely prominent role in normal development and cancer.
    Current Topics in Developmental Biology 01/2011; 94:129-69. DOI:10.1016/B978-0-12-380916-2.00005-X · 4.21 Impact Factor
  • Source
    • "E2F transcription factors regulate the expression of genes essential for the cell cycle transition, DNA replication, DNA synthesis, DNA repair and mitosis, and thus play crucial roles in cell proliferation, differentiation and apoptosis (DeGregori and Johnson, 2006; Korenjak and Brehm, 2005; Wu et al., 2001). Deletion of E2Fs causes hematopoietic progenitor and immune cell deficiency by disruption of the cell cycle, resulting in anemia and leucopenia (Gabellini et al., 2006; Korenjak and Brehm, 2005). E2F1-5 serve as both transcriptional activators and suppressors, whereas E2F6 suppresses E2F- responsive genes (Ogawa et al., 2002; Trimarchi et al., 1998). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Mutations in SMARCAL1 cause Schimke Immuno-Osseous Dysplasia (SIOD), an autosomal recessive multisystem developmental disease characterized by growth retardation, T-cell deficiency, bone marrow failure, anemia and renal failure. SMARCAL1 encodes an ATP-driven annealing helicase. However, the biological function of SMARCAL1 and the molecular basis of SIOD remain largely unclear. In this work, we cloned the zebrafish homologue of the human SMARCAL1 gene and found that smarcal1 regulated cell cycle progression. Morpholino knockdown of smarcal1 in zebrafish recapitulated developmental abnormalities in SIOD patients, including growth retardation, craniofacial abnormality, and haematopoietic and vascular defects. Lack of smarcal1 caused G0/G1 cell cycle arrest and induced cell apoptosis. Furthermore, using Electrophoretic Mobility Shift Assay and reporter assay, we found that SMARCAL1 was transcriptionally inhibited by E2F6, an important cell cycle regulator. Over-expression of E2F6 in zebrafish embryos reduced the expression of smarcal1 mRNA and induced developmental defects similar to those in smarcal1 morphants. These results suggest that SIOD may be caused by defects in cell cycle regulation. Our study provides a model of SIOD and reveals its cellular and molecular bases.
    Developmental Biology 03/2010; 339(1):89-100. DOI:10.1016/j.ydbio.2009.12.018 · 3.64 Impact Factor
Show more